Brief: Olix Pharmaceuticals Announces Expansion Of Collaboration With Laboratoires Théa To Develop Sirna Therapeutics For Ophthalmic Diseases
07/10/2020 14:24
Oct 7 (Reuters) - OliX Pharmaceuticals Inc 226950.KQ :
* OLIX PHARMACEUTICALS - ANNOUNCES EXPANSION OF
COLLABORATION WITH
LABORATOIRES THÉA TO DEVELOP SIRNA THERAPEUTICS FOR OPHTHALMIC
DISEASES
* OLIX PHARMACEUTICALS - COMPANIES TO BROADEN THEIR EXISTING
PARTNERSHIP ON AGE-RELATED MACULAR DEGENERATION (AMD) TREATMENTS
* OLIX PHARMACEUTICALS - OLIX GRANTS THÉA WORLDWIDE RIGHTS
EXCLUDING ASIA-PACIFIC ON OLX301A AND OLX301D
* OLIX PHARMACEUTICALS - OLIX FURTHER GRANTS THÉA OPTION TO
NOMINATE TWO ADDITIONAL OPHTHALMIC PROGRAMS
* OLIX PHARMACEUTICALS- THÉA TO INVEST EUR 8.8 MILLION
THROUGH
UPFRONT PAYMENT FOR 2 AMD PROGRAMS, OPTION FEE FOR 2 ADDITIONAL
OPHTHALMIC PROGRAMS
Source text for Eikon: ID:nGNX6WYKqv
Further company coverage: 226950.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment